Phase 2 Obesity Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men and postmenopausal women who are 50 years of age or older
- People with a Body Mass Index (BMI) of 30 or above (a measure of body weight relative to height)
- People whose blood sugar control (measured by a test called HbA1c) is below 6.5% and who are not currently taking any medication to lower blood sugar
- People who are willing and able to follow all study requirements, including fasting before certain visits
- People who are able to give informed consent and take part in all study assessments
Who may not be able to join:
- People who have an active diagnosis of type 2 diabetes, meaning those currently taking blood sugar-lowering medications or whose HbA1c blood test result is 6.5% or higher
- People with a BMI of 40 or above
- People with a history of moderate to severe acid reflux (gastroesophageal reflux disease)
- People who are unable to follow the treatment plan or understand the consent form
- People with stage 4 chronic kidney disease (a serious level of reduced kidney function)
- People whose liver enzyme levels (measured by blood tests called AST or ALT) are above certain limits set by the trial (confirm with trial site)
- People who are currently pregnant
- People with a personal or family history of a type of thyroid cancer called medullary thyroid carcinoma
- People with a personal or family history of a condition called multiple endocrine neoplasia type 2 syndrome
- People with a personal history of gastroparesis (a condition where the stomach empties too slowly)
- People with a personal history of diabetic retinopathy (eye damage related to diabetes)
- People with a known serious allergic reaction, including severe allergy or swelling reactions, to the study drug Tirzepatide or any of its ingredients
- People with a known serious allergic reaction to any medication in the GLP-1 receptor agonist drug class (a group of medicines used to manage blood sugar and weight)
- People who are currently being treated with a GLP-1 receptor agonist medication
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Shreya Rao, MD, MPH, The University of Texas Health Science Center at San Antonio
Phone: (210)450-3333
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Appendicular lean muscle mass; Muscle Strength; Lower Extremity Functional Capacity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.